Indivior PLC Directorate Change
RNS Number : 2672L
11 January 2021
Indivior PLC - Directorate Change
Indivior PLC announces that Daniel Tassé has notified the Board
of his intention to stand down as a Non-Executive Director of the
Company in order to focus on his increasing business commitments.
Mr Tassé will not stand for re-election at the Company's next
Annual General Meeting and will stand down at the conclusion of
Daniel Tassé has been a Non-Executive Director for over six
years and is currently Senior Independent Director, Chair of the
Audit Committee and a member of the Remuneration Committee. As
announced in November 2020, a search is underway to identify an
additional independent Non-Executive Director with recent and
relevant financial experience and the search has been expanded to
identify a further Non-Executive Director.
Graham Hetherington, Chair of the Board of Indivior PLC,
'Daniel joined the Board in 2014 and was appointed Senior
Independent Director in 2016. He has been a strong contributor
since the Company's listing. His strategic and commercial
experience and acumen have been invaluable, as was his strong
leadership while stepping in as Interim Chair in June 2020 at a
critical time for the Company. On behalf of the entire Board, I
would like to extend our thanks to Daniel and wish him well.
This announcement is made pursuant to Listing Rule
January 11, 2021
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat addiction
and serious mental illnesses. Our vision is that all patients
around the world will have access to evidence-based treatment for
the chronic conditions and co-occurring disorders of addiction.
Indivior is dedicated to transforming addiction from a global human
crisis to a recognized and treated chronic disease.
Building on its global portfolio of opioid dependence
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of
addiction, including alcohol use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more than 700
individuals globally and its portfolio of products is available in
over 40 countries worldwide. Visit www.indivior.com to learn more.
Connect with Indivior on LinkedIn by visiting
Investor Contact :
Jason Thompson, Indivior
Vice President, Investor Relations
Media Contacts :
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
January 11, 2021 08:00 ET (13:00 GMT)
Historical Stock Chart
From Aug 2021 to Sep 2021
Historical Stock Chart
From Sep 2020 to Sep 2021